Enlarge/ The exterior of the headquarters of biotechnology company Biogen in Cambridge, Massachusetts.
47 with 37 posters participating
Biogen’s new Alzheimer’s drug Aduhelm continues to face opposition after its contentious approval by the Food and Drug…

Click here to view the original article.